A phase 1/2, open-label safety and dose-finding study of AAV8-mediated gene transfer of human OTC in adult late-onset OTCD patients has completed recruitment (CAPtivate, NCT02991144). This evidence concerns the gene OTC and ornithine carbamoyltransferase deficiency.